Genetic Testing

UMC Utrecht adopts Volta Labs Callisto Sample Prep System to process thousands of samples for Whole Genome Sequencing-based prenatal and postnatal testing

Staff February 5, 2025

BOSTON, Feb. 5, 2025 /PRNewswire/ -- Volta Labs, a leading genomics applications company, and UMC Utrecht, one of the largest public...

Myriad Genetics Unveils Groundbreaking Eight Weeks’ Gestation NIPT Study Results at Society for Maternal-Fetal Medicine Conference

Staff January 29, 2025

Opening plenary session features latest fetal fraction amplification researchSALT LAKE CITY, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc....

Global Wellness Summit Releases 10 Wellness Trends for 2025

Staff January 28, 2025

In a polarized wellness market, we'll see both "analog wellness" (a great logging off and seizing of pre-digital experiences) and...

Myriad Genetics Introduces Online Prenatal Genetic Testing Resource

Staff January 23, 2025

SALT LAKE CITY, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and...

Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology

Staff January 21, 2025

Study showed online screening tool and patient education improved genetic testing completion rateSALT LAKE CITY, Jan. 21, 2025 (GLOBE NEWSWIRE)...

Applied DNA Completes Buildout of GMP Facility for LineaDNA IVT Templates

Staff January 10, 2025

- Signals Start of New Commercialization Phase for LineaRx Subsidiary -- Company Negotiating GMP Supply Agreement -- Company Reaffirms Strategic...

Hydreight Technologies Provides Shareholder Update on 2024 Milestones and 2025 Vision

Staff January 9, 2025

VANCOUVER, British Columbia and LAS VEGAS, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (“Hydreight” or the “Company”) (TSXV:...

MONCYTE Health Joins International Consortium for Earlier Diagnosis and Management of Familial Hypercholesterolemia

Staff January 9, 2025

EUR 7 million Horizon Europe funded FH-EARLY project on world’s most common inherited metabolic disorderHELSINKI, Jan. 09, 2025 (GLOBE NEWSWIRE)...

Applied DNA Reschedules Investor Update Call in Observance of the National Day of Mourning in Recognition of the Passing of Former President Jimmy Carter

Staff January 8, 2025

STONY BROOK, NY / ACCESSWIRE / January 8, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"),...

Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Staff January 8, 2025

SALT LAKE CITY, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and...

Myriad Genetics Issues Quality, Innovation, and Corporate Responsibility Report

Staff January 6, 2025

SALT LAKE CITY, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and...

Applied DNA Customer ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-Cell Therapy Produced from Linea DNA

Staff December 18, 2024

- Regulatory Approval Showcases Clinical Advancement of Linea DNA™ as a Rapid and Effective Means of Producing CAR-T cell Therapies...

Applied DNA Announces Fourth Quarter and Fiscal Year 2024 Financial Results, Announces Strategic Restructuring to Prioritize the Manufacture of Critical Starting Materials for Genetic Medicines

Staff December 17, 2024

- Pursuing Divestiture of CertainT® Platform, Implements Changes to Corporate Leadership -- Build-out of GMP Manufacturing Facility to be Completed...

Applied DNA to Report Fourth Quarter and Fiscal Year 2024 Financial Results After Market Close on December 17, 2024; Sets Webcast and Conference Call for January 9, 2025, to Coincide with Update on GMP Manufacturing Facility Build-out

Staff December 16, 2024

STONY BROOK, NY / ACCESSWIRE / December 16, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"),...

Dr. Christina Campbell and Dr. Bruce Phillips launch “Hack The Code” Program for Weight Management

Staff December 12, 2024

This program offered by the healthcare professional duo provides a solution to weight management backed by insights through genetic testing ...

NCCN Prostate Cancer Guidelines Reinforce Status of Myriad Genetics’ Prolaris® Test as an ‘Advanced Tool’ Recommended for Prognostic Assessment

Staff December 9, 2024

Prolaris Remains a Long-Standing Fixture in the Guidelines for 10th Year RunningSALT LAKE CITY, Dec. 09, 2024 (GLOBE NEWSWIRE) --...

Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson’s Disease

Staff December 5, 2024

SOUTH SAN FRANCISCO, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced initiation of dosing...

My Compounding of Brisbane Now Offers Compounding Services Across Australia

Staff November 26, 2024

BRISBANE, AUSTRALIA / ACCESSWIRE / November 26, 2024 / The healthcare landscape in Australia has taken a significant stride forward...

Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide

Staff November 18, 2024

-- Four Pediatric patients treated in French early-access program achieved meaningful weight reduction at three months on setmelanotide therapy --...

CMTA and INC Forge Groundbreaking Alliance to Accelerate Comprehensive Research Across All Charcot-Marie-Tooth Disease Types

Staff November 13, 2024

CMTA strengthens its role as the leading force in comprehensive CMT research, forging a new strategic alliance with the Inherited...